The United States Patent and Trademark Office’s (USPTO) May 14, 2026, precedential decision in Magnolia Medical Technologies v. Kurin warrants careful scrutiny from the congressional committees with jurisdiction over patent law. The decision purports to restore the Patent Trial and Appeal Board to its original congressional design. A close reading of the legislative record suggests otherwise.
The Statutory Purpose of IPR
Magnolia’s foundational premise — that Inter Partes Review (IPR) was created primarily as an alternative to litigation, and that petitioners already in court are misusing the process — is a selective and incomplete reading of the America Invents Act’s (AIA) legislative record. The House Judiciary Committee Report states that Congress sought “to establish a more efficient and streamlined patent system that will improve patent quality and limit unnecessary and counterproductive litigation costs,” H.R. Rep. No. 112-98, at 40 (2011). The Congressional Record is consistent: The AIA should “strengthen patent quality and reduce costs,” given that “litigation over invalid patents places a substantial burden on US courts and the US economy,” 157 Cong. Rec. 13166 (2011). Magnolia elevates a subordinate “alternative to litigation” phrase to a governing principle while setting aside the dominant patent quality theme Congress actually expressed.
The Trump administration’s own Solicitor General made this point before the Supreme Court in Oil States, arguing that Congress enacted IPR to “improve patent quality and restore confidence in the presumption of validity that comes with issued patents” — not as a litigation substitute. The Court agreed, 7-2. Oil States Energy Servs., LLC v. Greene’s Energy Grp., LLC, 584 U.S. 325 (2018).
The Parallel Litigation Problem Is Misdiagnosed
Magnolia’s parallel litigation argument also turns the IPR process on its head. The decision laments that “many petitioners seek AIA review in parallel with litigation,” as if that were evidence of bad faith. But who are these petitioners? They are typically companies that have first been targeted with a specious assertion of infringing an invalid patent claim. Magnolia blames the victims of these frivolous assertions for invoking their rights to a congressionally mandated, expert review of USPTO examination errors, while deeming harmless the predatory tactics of Non-Practicing Entities (NPEs) seeking to monetize those errors. USPTO has it exactly backwards. Furthermore, parallel proceedings persist largely because courts in the Eastern and Western Districts of Texas routinely decline to stay litigation while IPR proceeds. The appropriate response is to address district court venue and stay practice, not restrict access to an administrative proceeding Congress specifically designed for the purpose of improving patent quality and reducing costly and unnecessary litigation.
Existing Safeguards and the Statistical Record
Magnolia’s abuse concerns also overlook the safeguards Congress already built into the AIA. IPR proceedings are limited to specific grounds; must conclude within one year; cannot be filed more than one year after service of a complaint; and trigger broad estoppel after a final written decision. Congress further empowered USPTO to sanction petitioners who misuse the process. These are deliberate design choices, not gaps in the law.
The statistical record does not support the premise of widespread abuse either. In 2024, out of approximately 3.9 million live US patents, fewer than 350 — roughly 0.009 percent — were even partially invalidated by the Patent Trial and Appeal Board. Serial petitions account for a mere 0.3 percent of all instituted IPRs. What the data do show, however, is a dramatic and troubling collapse in institution rates: USPTO instituted roughly 70 percent of petitions for most of the IPR program’s history; that figure dropped to approximately 20 percent in the period immediately following Director Squires’ appointment. The decline is not a function of petition quality — it is a function of the Director’s preferences regarding discretionary denials. Furthermore, in the same time period, NPE litigation filings in district court rose sharply. The Judiciary Committees should examine whether that policy is consistent with the statutory standard Congress established in 35 U.S.C. § 314(a).
Declining to institute meritorious IPR petitions does not strengthen the patent system. It insulates examination errors from correction and leaves likely invalid claims available for assertion against productive companies. The IPR process was designed to produce stronger, more reliable patents, and Congress built sufficient safeguards to ensure it operates fairly. Restricting access to that process, without statutory authority and contrary to the legislative record, is not reform. It is a departure from the law Congress enacted.
